|
|
|
| Expression and functional study of chimeric antibodies targeting SARS-CoV-2 receptor binding domain |
| SHI Huichun1, JIAO Fanke2, 3, XU Wei2, 3, CHEN Yongkang2, 3, LU Lu2, 3, ZOU Peng1 |
| 1. Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; 2. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China; 3. Shanghai Institute of Infectious Disease and Biosecurity, Shanghai 200032, China |
|
|
|
| Guide |
|
|
Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has a serious impact on people’s health and lives. At present, SARS-CoV-2 is still widely spread, but effective treatments for SARS-CoV-2 are still limited. Therefore, it is of great significance to find broad-spectrum neutralizing antibodies to block SARS-CoV-2 infection. In this study, we successfully expressed and purified three human-mouse chimeric antibodies targeting receptor-binding domain (RBD) of SARS-CoV-2, and then the neutralizing activities of these antibodies against a variety of SARS-CoV-2 pseudoviruses and authentic virus were tested. The results showed that these three antibodies could specifically neutralize SARS-CoV-2 wild-type pseudovirus, and the IC50 values were 0.03 μg/mL, 0.06 μg/mL and 0.03 μg/mL, respectively. Furthermore, these antibodies exhibited broad-spectrum neutralizing activity against Alpha, Delta and Lambda pseudoviruses, and could also inhibit the replication of SARS-CoV-2 Delta authentic virus. Mechanism studies showed that these antibodies could block cell-cell fusion mediated by SARS-CoV-2 S protein, and K417, E484 and N501 on receptor-binding domain (RBD) may be the key sites for binding with these three antibodies.
|
|
Received: 14 October 2022
Published: 25 February 2023
|
|
|
| Fund: |
|
Corresponding Authors:
ZOU Peng
|
|
|
|
|
|
|
2023, Vol. 18 
